Better Therapeutics- Tradeable Rights - March 2021 Debt to Equity

Better Therapeutics- Tradeable Rights - March 2021's debt-to-equity ratio stands at -1.44. That is below the sector sector average of 0.14. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Better Therapeutics- Tradeable Rights - March 2021 sits lower the its sector benchmark (0.14) with a debt-to-equity ratio of -1.44. That is roughly 1114.8% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether -1.44 is attractive depends on Better Therapeutics- Tradeable Rights - March 2021's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Better Therapeutics- Tradeable Rights - March 2021's debt-to-equity ratio evolved across reporting periods, while the comparison chart places MCADR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.